Kennedy Capital Management, Inc. Nurix Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.23 Billion
- Q4 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 114,623 shares of NRIX stock, worth $1.53 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
114,623
Previous 113,838
0.69%
Holding current value
$1.53 Million
Previous $2.56 Million
15.5%
% of portfolio
0.05%
Previous 0.06%
Shares
7 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$58 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$55.9 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$51.8 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$40.1 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $629M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...